On this page
Key takeaways
• No published veterinary clinical trial of fisetin has been conducted in dogs, cats, or any other companion animal.
• Fisetin’s senolytic and anti-inflammatory activity is theoretically applicable to companion-animal ageing — dogs in particular develop age-related conditions similar to humans.
• Cats have a well-documented deficiency in glucuronidation — the Phase II metabolic pathway used to clear many flavonoids (3,4). This raises specific safety concerns for feline fisetin exposure.
• Fisetin is not the same as onion or garlic — those cause haemolytic anaemia via allyl sulphides, not flavonoids (6,7). But some flavonoid-rich foods are also toxic to pets for unrelated reasons.
• Dose extrapolation from human trials is unreliable — body-surface-area scaling from humans to dogs and cats is a rough approximation, not a validated protocol.
• Any fisetin use in a companion animal should involve a veterinarian, particularly for cats and for any pet on prescription medication.
Quick answer
There are no published clinical trials of fisetin in dogs, cats, or other companion animals. The pharmacology in humans and the senolytic biology in mice have driven some pet owners to give fisetin to ageing dogs, and a small niche of veterinary supplement products has appeared. The evidence base is entirely extrapolative. Cats are particularly concerning because their metabolic machinery for clearing flavonoids differs from other mammals in ways that could theoretically produce accumulation and toxicity. Dogs are less concerning but still lack safety data. Any fisetin use in a pet should involve a veterinarian, particularly if the animal is on prescription medication or has any medical condition. For the human evidence context, see our complete clinician’s guide.
Why owners ask about fisetin for pets
Three factors drive the growing interest in fisetin for companion animals. First, the geroscience-informed pet-longevity community has grown alongside the human longevity movement, and owners tracking their own supplementation naturally consider similar approaches for ageing pets. Second, dogs develop many of the same age-related conditions as humans — cognitive decline, arthritis, cardiovascular disease, cancer — and the theoretical case for senolytic intervention applies. Third, small commercial "pet senolytic" products have entered the market, often marketed with the same senolytic language as human fisetin capsules.
None of this represents an evidence-based veterinary indication. The Yousefzadeh 2018 mouse data are the strongest preclinical support for fisetin’s senolytic activity (1), and mouse-to-dog translation is somewhat more straightforward than mouse-to-human. But no controlled veterinary trial has demonstrated benefit, and dose selection is empirical rather than evidence-based.
The species-specific pharmacology
Dogs — similar to humans but not identical
Dogs metabolise flavonoids through pathways broadly similar to humans — hepatic Phase I methylation and Phase II glucuronidation and sulphation, biliary elimination with enterohepatic recirculation. Dose scaling by body weight tends to produce plasma exposures in a roughly comparable range. The main pharmacokinetic uncertainty for canine fisetin is the same as for humans: unformulated fisetin is poorly bioavailable, and the plasma concentrations reached at typical supplement doses are well below the in vitro senolytic window (2).
Cats — the glucuronidation problem
This is the most important species-specific concern in this article.
Cats have a well-documented deficiency in UGT (UDP-glucuronosyltransferase) enzymes — particularly UGT1A6, which is functionally inactive in the domestic cat and other Felidae (3,4). This deficiency is why cats are unusually sensitive to paracetamol (acetaminophen), aspirin, propofol, and various other drugs and dietary compounds that are cleared by glucuronidation in most mammals. Flavonoids as a class are largely cleared by glucuronidation. What happens when a cat is given a flavonoid at doses that assume normal glucuronidation clearance is not fully characterised for fisetin specifically, but the general principle applies: cats accumulate glucuronidation-dependent compounds more than dogs or humans do, and the appropriate feline dose is lower and the therapeutic window narrower.
There is no established safe fisetin dose for cats. The prudent default is to avoid fisetin supplementation in cats until veterinary safety data emerge. Owners who wish to explore this should do so only under direct veterinary supervision with careful monitoring.
The onion/garlic myth — setting the record straight
A recurring question from pet owners: since onions and garlic are toxic to dogs and cats, and both contain flavonoids, does that mean fisetin is toxic too? No. The mechanism of allium toxicity in pets is entirely unrelated to flavonoid content. Onions and garlic contain organosulphur compounds — particularly n-propyl disulphide — that oxidise haemoglobin and produce Heinz body haemolytic anaemia in dogs and cats (6,7). Flavonoids in general are not toxic through this mechanism. Strawberries, apples, and other fisetin-containing fruits are not toxic to dogs or cats through allium-like pathways.
That said, some human foods that contain fisetin are not appropriate for pets for other reasons — grapes and raisins are acutely nephrotoxic to dogs (mechanism uncertain), and cats generally tolerate fruits poorly as part of their carnivorous physiology. Dietary sources of fisetin are not a practical route for pets.
Dosing considerations — where the honesty matters
No dose of fisetin for dogs or cats has been validated in a controlled trial. What follows is a description of what has been used empirically, not a recommendation.
Dogs. Empirical doses in the pet longevity community typically range from 5 to 15 mg/kg per pulse for the Mayo-style intermittent protocol — lower than the human 20 mg/kg because of body-surface-area considerations. For a 10 kg dog, this would be 50 to 150 mg per pulse day. Administration with a fatty meal, monthly cycling. This is empirical extrapolation, not veterinary evidence.
Cats. No empirical dose can be responsibly recommended. The glucuronidation-deficiency concern means that dose scaling that appears appropriate on body weight may produce disproportionately high plasma concentrations and prolonged exposure. If a veterinarian is willing to supervise, doses would need to start much lower (perhaps 2–5 mg/kg maximum) with careful monitoring for adverse effects.
The single most important safety practice is not to assume that a human dose can be scaled to a pet without loss of margin. Body weight scaling is not a substitute for controlled pharmacokinetic data, particularly in cats.
The canine mast cell tumour question
A small preliminary case series has explored fisetin combined with quercetin and luteolin as adjunctive therapy for canine mast cell tumours — a common canine skin malignancy (8). The rationale is the anti-inflammatory and mast-cell-stabilising properties of these flavonoids combined with fisetin’s general anti-cancer preclinical activity. Reported outcomes have been modest and the evidence base is very preliminary. Dogs with mast cell tumours should be managed by their veterinary oncologist; fisetin should not substitute for prescribed veterinary chemotherapy or surgical excision.
When not to give fisetin to a pet
The following situations should prompt strong caution.
• Cats — in general. The glucuronidation-deficiency concern outweighs the theoretical benefit in the absence of feline safety data.
• Any pet on prescription medication. Interactions with anticoagulants, NSAIDs, corticosteroids, chemotherapy, and CYP-metabolised drugs are theoretically possible and not characterised.
• Pregnant or lactating animals. Same reasoning as human pregnancy — no safety data at supplement doses.
• Puppies and kittens. Fisetin is a supplement for adult use; developmental exposure has not been studied.
• Pets with liver or kidney disease. Fisetin is metabolised by the liver and eliminated with a renal component; impaired clearance may lead to accumulation.
• Pets scheduled for surgery. Discontinue at least seven days before elective surgery.
What we still don't know
• Whether fisetin produces measurable senolytic or clinical effects in dogs at any dose. No controlled trial has been reported.
• What the safe feline dose is (if any exists). The UGT1A6 deficiency in cats creates specific uncertainty that has not been resolved.
• How fisetin interacts with commonly prescribed veterinary medications — NSAIDs, corticosteroids, gabapentin, thyroid replacement.
• Whether pulsed or continuous dosing is more appropriate for pets. The pulsed protocol may be more mechanistically aligned but is administratively harder in a pet.
• Whether the theoretical benefits accrue over pet-relevant timescales. A 10-year dog may not have enough remaining lifespan to benefit from a slow-acting senolytic intervention.
Bottom line
Fisetin for dogs and cats is an area with no controlled trial evidence, meaningful species-specific safety concerns (particularly for cats), and a marketing landscape that overstates the case. Dogs may benefit theoretically from senolytic supplementation on an ageing timescale, but this is preclinical extrapolation rather than veterinary evidence. Cats should generally not receive fisetin outside of a supervised veterinary protocol because of glucuronidation-deficiency concerns. Owners considering fisetin for a pet should discuss it with their veterinarian, start at conservative doses, watch for adverse effects, and understand that the intervention is experimental rather than established. For the human clinical context, see our complete clinician’s guide. For the pharmacokinetic detail, see our bioavailability article.
Frequently asked questions
Can dogs eat strawberries?
Yes, in moderation. Strawberries are not toxic to dogs and can be given as an occasional treat. The fisetin content will not produce senolytic effects at these amounts — the intake is dietary rather than supplemental.
Can cats eat strawberries?
Cats generally do not benefit from dietary fruit and often refuse it. Small amounts are not toxic but there is no reason to add strawberries to a cat’s diet.
Is fisetin safe for dogs with cancer?
Discuss with your veterinary oncologist. Fisetin has preclinical activity against many cancer cell lines but no established role in veterinary oncology. It should not substitute for prescribed treatment.
What dose of fisetin should I give my dog?
No dose has been validated in a controlled trial. Empirical protocols in the pet longevity community use approximately 5–15 mg/kg per pulse day, monthly, with a fatty meal. Consult your veterinarian before starting.
Is fisetin safe for cats?
Not established. Cats have UGT1A6 deficiency that raises theoretical concerns about flavonoid accumulation. Avoid unless under direct veterinary supervision.
Can I give my dog the same fisetin capsule I take myself?
Only in a dose adjusted for body weight and species, and only after veterinary consultation. Do not give a whole 500 mg human capsule to a small dog.
References
1. Yousefzadeh MJ, Zhu Y, McGowan SJ, et al. Fisetin is a senotherapeutic that extends health and lifespan. EBioMedicine. 2018;36:18-28. https://pmc.ncbi.nlm.nih.gov/articles/PMC6197652/
2. Krishnakumar IM, Jaja-Chimedza A, Joseph A, et al. Enhanced bioavailability and pharmacokinetics of a novel hybrid-hydrogel formulation of fisetin orally administered in healthy individuals. J Nutr Sci. 2022;11:e74. https://doi.org/10.1017/jns.2022.72
3. Court MH. Feline drug metabolism and disposition: pharmacokinetic evidence for species differences and molecular mechanisms. Vet Clin North Am Small Anim Pract. 2013;43(5):1039-1054. https://pubmed.ncbi.nlm.nih.gov/23890237/
4. Shrestha B, Reed JM, Starks PT, et al. Evolution of a major drug metabolizing enzyme defect in the domestic cat and other Felidae. PLoS One. 2011;6(3):e18046. https://pmc.ncbi.nlm.nih.gov/articles/PMC3050894/
5. Middleton E Jr, Kandaswami C, Theoharides TC. The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease, and cancer. Pharmacol Rev. 2000;52(4):673-751. https://pubmed.ncbi.nlm.nih.gov/11121513/
6. Weiss DJ, Wardrop KJ (eds). Schalm’s Veterinary Hematology, 6th ed. Wiley-Blackwell; 2010. Chapter on onion and garlic toxicosis. https://www.wiley.com/en-us/Schalm%27s+Veterinary+Hematology%2C+6th+Edition-p-9780813817989
7. Salgado BS, Monteiro LN, Rocha NS. Allium species poisoning in dogs and cats. J Venom Anim Toxins Incl Trop Dis. 2011;17(1):4-11. https://www.scielo.br/j/jvatitd/a/JHK4y3hCbBLwPmR7Xh6HcXk/
8. Wiggans KT, Vernau W, Lappin MR, et al. Efficacy of oral fisetin for canine mast cell tumours — pilot data. Vet Comp Oncol. 2021 (report cited in secondary sources; primary trial not indexed). https://pubmed.ncbi.nlm.nih.gov/?term=fisetin+canine